Table 9 The impact of metabolic phenotypes on prognosis by univariate analysis
From: Metabolic phenotypes in primary unknown metastatic carcinoma
| Clinicopathologic parameters | No. of patients (n = 59*) (%) | Overall survival | ||
|---|---|---|---|---|
| No. of cases | Patient death | Median survival (95% CI) (months) | P -value | |
| Tumor metabolic type | 0.279 | |||
| Glycolysis type | 22 | 5 | 52 (37–67) | |
| Non-glycolysis type | 37 | 13 | 79 (56–102) | |
| Tumor metabolic type | 0.644 | |||
| Glutaminolysis type | 30 | 10 | 84 (60–108) | |
| Non-glutaminolysis type | 29 | 8 | 45 (30–59) | |
| Tumor metabolic type | 0.906 | |||
| Mitochondrial type | 56 | 17 | 84 (66–103) | |
| Non-mitochondrial type | 3 | 1 | 28 (13–43) | |
| Stroma metabolic type | n/a | |||
| Glycolysis type | 2 | 0 | n/a | |
| Non-glycolysis type | 57 | 18 | n/a | |
| Stroma metabolic type | 0.363 | |||
| Glutaminolysis type | 7 | 1 | 62 (43–80) | |
| Non-glutaminolysis type | 52 | 17 | 80 (60–100) | |
| Stroma metabolic type | 0.864 | |||
| Mitochondrial type | 9 | 2 | 28 (18–37) | |
| Non-mitochondrial type | 50 | 16 | 83 (64–103) | |
